Left Atrial Appendage Occlusion in Patients With Thrombus in Left Atrial Appendage

Atrial appendage (LAA) occlusion is a therapeutic option for thromboembolic prevention in atrial fibrillation (AF) patients who have contraindications to oral anticoagulation (OAC) or high risk of bleeding. Traditionally, thrombus in the LAA has been considered a contraindication for LAA occlusion....

Full description

Saved in:
Bibliographic Details
Published in:The Journal of invasive cardiology 2020-06, Vol.32 (6), p.222
Main Authors: Sahiner, Levent, Coteli, Cem, Kaya, Ergun Baris, Ates, Ahmet, Kilic, Gul Sinem, Yorgun, Hikmet, Aytemir, Kudret
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Atrial Appendage - diagnostic imaging
Atrial Appendage - surgery
Atrial Fibrillation - complications
Atrial Fibrillation - diagnosis
Echocardiography, Transesophageal
Humans
Middle Aged
Septal Occluder Device
Stroke - diagnosis
Stroke - etiology
Stroke - prevention & control
Thrombosis - diagnosis
Thrombosis - etiology
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atrial appendage (LAA) occlusion is a therapeutic option for thromboembolic prevention in atrial fibrillation (AF) patients who have contraindications to oral anticoagulation (OAC) or high risk of bleeding. Traditionally, thrombus in the LAA has been considered a contraindication for LAA occlusion. Recently, resistant thrombus formation in patients using OACs was suggested as an indication for LAA occlusion. In this single-center study, we evaluated the safety and efficacy of LAA occlusion in patients with a thrombus in the LAA. Twelve non-valvular AF patients who had a thrombus in the LAA were enrolled. The mean age was 71.8 years (range, 62-83 years). Permanent AF was present in all patients. Mean CHA2DS2-VASc score was 4.9 (range, 2-8) and mean HAS-BLED score was 4.8 (range, 3-6). Thrombi in the LAA were classified as type 1 (proximal to mid) and type 2 (distal) in 3 and 9 patients, respectively. Median follow-up duration was 12 months (interquartile range, 6-24 months). LAA occlusion was performed successfully with Amplatzer Amulet device without any significant periprocedural adverse events in all 12 patients. Transesophageal echocardiography (TEE) was performed at 1 and 6 months post procedure. Cardiovascular and all-cause mortality, significant ischemic cerebrovascular events, worsening heart failure, and major bleeding events did not occur during follow-up. Device-related thrombus was not observed with TEE in any patient. Our study showed that percutaneous LAA closure could be a therapeutic option for patients with resistant LAA thrombus.
ISSN:1557-2501
1557-2501
DOI:10.25270/jic/1900392